All In Biotech

Drug Trial Radar · NCT05347069

Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization

Last checked: Nov 20, 2026Latest source record: Mar 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 2,890 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,890

Planned (sponsor's estimate)

Start

Jun 14, 2022

Primary completion

Mar 2030

Study completion Dec 2030

Sponsor

Lead sponsor
Takeshi MorimotoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety aspirin in patients with chronic coronary syndromes without revascularization.

Conditions

  • Stable Angina Pectoris
  • Coronary Artery Disease
  • Ischemic Heart Disease

Interventions

  • AspirinDrug

    Aspirin 100 mg/day

  • No aspirinDrug

    No aspirin administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite cardiovascular eventsTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kyoto University Hospital

    Kyoto, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.